Consensus Amgen Inc. Thailand S.E.

Stocks

AMGN06

TH0842123901

Pharmaceuticals

End-of-day quote Thailand S.E. 22/10/2026			5-day change	1st Jan Change
3.720 ^THB	+1.64%		+2.76%	-

10-25	Roche Targets Emerging Oncology Market With New Lung-Cancer Drug	DJ
10-25	AstraZeneca's Imfinzi Combo Therapy Reduces Death Risk in Late-stage Small Cell Lung Cancer Trial	MT

e.4KupF48MVUs1nYYiOyNGbygzfOQKmTYi_L_ybM8vq48.rJzldMZpChpQq9VaSxMrXXlZKNY8yV5vvceLLfYXnfa1kplV2T89HQXytg~3fc4c8c1c6e774c0f150428893bcfb55

Analysts' recommendations: Amgen Inc.

10-23	Amgen's Growth Drivers, Pipeline Could Support Longer-Term Outlook, Oppenheimer Says	MT
10-23	Oppenheimer Adjusts Amgen Price Target to $480 From $450, Maintains Outperform Rating	MT
10-21	Barclays Adjusts Price Target on Amgen to $400 From $380	MT
10-15	Goldman Sachs Adjusts Price Target on Amgen to $481 From $475	MT
10-13	Goldman Sachs Adjusts Price Target on Amgen to $475 From $450	MT
10-12	Amgen's Q3 Results Should Reflect Continued Commercial Momentum, BofA Securities Says	MT
10-12	BofA Securities Adjusts Amgen Price Target to $328 From $317, Maintains Underperform Rating	MT
10-12	Wells Fargo Adjusts Price Target on Amgen to $430 From $435	MT
10-12	BMO Capital Adjusts Price Target on Amgen to $415 From $450	MT
10-09	UBS Adjusts Price Target on Amgen to $470 From $430, Maintains Buy Rating	MT
10-08	RBC Raises Price Target on Amgen to $430 From $400, Keeps Outperform Rating	MT
10-07	Morgan Stanley Adjusts Price Target on Amgen to $359 From $362	MT
09-28	Scotiabank Raises Amgen Price Target to $500 From $450, Sector Outperform Rating Kept	MT
09-23	Jefferies Adjusts Amgen Price Target to $410 From $367, Maintains Hold Rating	MT
09-10	HSBC Downgrades Amgen to Hold From Buy, Adjusts Price Target to $425 From $445	MT
09-08	Amgen's Olpasiran May Still Show Heart-Risk Reduction Despite Novartis Miss, UBS Says	MT
09-08	Rothschild & Co Redburn Adjusts Price Target on Amgen to $225 From $235, Keeps Sell Rating	MT
09-08	BMO Capital Downgrades Amgen to Market Perform From Outperform, Price Target is $450	MT
09-08	Analyst recommendations: Amgen, Equifax, Lockheed Martin, Phillips 66, Valero Energy…
09-07	Analyst recommendations: Amgen, Broadcom, Lululemon, Palo Alto Networks…
09-04	Wells Fargo Adjusts Price Target on Amgen to $435 From $400, Keeps Equalweight Rating	MT
08-20	Piper Sandler Adjusts Price Target on Amgen to $457 From $427, Maintains Overweight Rating	MT
08-19	Argus Research Adjusts Amgen Price Target to $460 From $375, Maintains Buy Rating	MT
08-19	Morgan Stanley Adjusts Price Target on Amgen to $362 From $351, Keeps Equalweight Rating	MT
08-18	Mizuho Adjusts Price Target on Amgen to $352 From $303, Maintains Neutral Rating	MT

More recommendations

Other Pharmaceuticals

	Add to a list 0 selected To use this feature you must be a member Log in Sign up	Consensus	Analysts' recommendations evolution (4 months)	Financial estimates divergence	Analysts' Target price divergence	Objective/dr gap
	ELI LILLY AND COMPANY					+4.56%
	JOHNSON & JOHNSON					+5.91%
	ABBVIE INC.					-0.3%
	ROCHE HOLDING AG					-1.29%
	MERCK & CO., INC.					+9.97%
	NOVARTIS AG					-1.87%
	ASTRAZENECA PLC					+22.49%
	AMGEN INC.					-9.69%
	GILEAD SCIENCES, INC.					+2.66%
	Average					+3.61%
	Weighted average by Cap.					+3.88%